ESC 2022 | REVIVED-BCIS2

The REVIVED-BCI2 included 700 patients with ejection fraction 35% with extended coronary artery disease and plausible PCI.

ESC 2022

Patients were randomized to PCI plus optimal and complete medical treatment (OMT) according to the current guidelines.

347 patients received PCI and 353 OMT.

Primary end point was all cause death and hospitalization for cardiac failure. 

There were no differences between the populations.

At 11-month follow-up, there were no differences in primary end point (PCI 37.2% vs OMT 38%). Neither were there differences in primary end point components or the presence of AMI. 

The need for unplanned revascularization and myocardial ischemia were more frequent in patients receiving OMT.

Ejection fraction at 2 years was 27% at 6 and 12 months with no difference between the strategies. 

Read also: ESC 2022 | PERSPECTIVE: Efficacy and Safety of Sacubitril/Valsartan Compared with Valsartan in Cognitive Function of Patients with Cardiac Failure and Preserved Function.

Quality of life, according to the Kansas City Cardiomyopathy Questionnaire (KCCQ), was superior in patients receiving PCI at 6 months but with no difference at 2 years. 

We can conclude that this study on patients with severe ventricular dysfunction undergoing OMT at maximal tolerable doses, revascularization with PCI did not result in lower incidence of all cause death or hospitalization for cardiac failure. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...